CEL-SCI prices $2.5 million share offering at $1.00 per share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
CEL-SCI Corporation Announces Pricing of Offering
June 14, 2026 7:03 PM EDTVIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (CEL-SCI or the Company) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 2,500,000 shares of common stock at an offering price of $1.00 per share. Total gross proceeds from the offering, before deducting the placement agents fees and offering expenses, are expected to be $2.5 million. The offering is expected to close on June 16, 2026, subject to satisfaction of customary closing conditions.
The Company intends to use the proceeds for the continued development of Multikine*, general corporate purposes, and working... More
